• 149% increase in revenue to $31.3 million
• 124% increase in net profit to $7.3 million
• Expanded manufacturing capacity and international footprint

Bioxyne Limited, an Australian pharmaceutical company, has reported record financial results for the half-year ended 31 December 2025. The company's revenue increased by 149% to $31.3 million, up from $12.6 million in the prior corresponding period. Net profit after tax grew by 124% to $7.3 million, compared to $3.3 million in H1 FY25. The strong performance was underpinned by sustained and increasing demand for the company's GMP-manufactured cannabis, MDMA and psilocybin medicinal products, as well as the successful scaling of Bioxyne's manufacturing and distribution capabilities. The company's Australian operations expanded output to service new domestic contract wins and rising international demand, including exports to Germany and the United Kingdom. Breathe Life Sciences, Bioxyne's wholly-owned subsidiary, continued to experience strong demand across its core medicinal cannabis portfolio, including flower, oils, vaporisers, capsules and pastilles. The company also achieved a significant milestone with the commercial release and supply of the first Australian-made GMP-certified MDMA capsules. Bioxyne's international footprint expanded materially during the period, with entry into the German market and the execution of a distribution agreement for Costa Rica and Panama. The company also secured non-dilutive funding to establish a GMP manufacturing facility in Scotland, advancing its European production capabilities.

Bioxyne provided revenue and EBITDA guidance for the FY30 June 2026 to be $65 to $75 million and $11.5 to $13.5 million, respectively.

Bioxyne maintains its strategic focus on pharmaceutical manufacturing and wholesale distribution of its product portfolio, which currently includes cannabis, MDMA, and psilocybin. The company expects its international operations to continue scaling and contribute a larger proportion of revenue in the subsequent half year as it enters new markets in Europe and Latin America.